Drugs.com - Clinical Trials

Incyte Announces Positive Topline Results From Two Phase 3 Clinical Trials of Povorcitinib in Patients With Hidradenitis Suppurativa

WILMINGTON, Del.--(BUSINESS WIRE)--Mar. 17, 2025-- Incyte (Nasdaq: INCY) today announced positive topline results from its pivotal Phase 3 STOP-HS clinical trial program evaluating the safety and efficacy of povorcitinib (INCB054707), an oral...

Mar 18, 2025 - 07:11
 0
Incyte Announces Positive Topline Results From Two Phase 3 Clinical Trials of Povorcitinib in Patients With Hidradenitis Suppurativa
WILMINGTON, Del.--(BUSINESS WIRE)--Mar. 17, 2025-- Incyte (Nasdaq: INCY) today announced positive topline results from its pivotal Phase 3 STOP-HS clinical trial program evaluating the safety and efficacy of povorcitinib (INCB054707), an oral...
Read More

Tags:

Previous Article

Ulta Beauty Admits Rocky Road Ahead Amid Consumer Uncertainty

Next Article

SCORPIO-PEP Phase 3 Trial: Ensitrelvir is the First and Only COVID-19 Oral Antiv...

Related Posts

Eneboparatide Met Primary Endpoint of Normalising Serum Calcium in Adults with Hypoparathyroidism at 24 weeks in CALYPSO Phase III Trial

Eneboparatide Met Primary Endpoint of Normalising Serum...

Mar 17, 2025  0

Cingulate Reports Safety Results from Final Phase 3 Trials for Lead ADHD Asset CTx-1301

Cingulate Reports Safety Results from Final Phase 3 Tri...

Mar 5, 2025  0

Depemokimab Delivers Clinically Meaningful and Statistically Significant Improvements for Patients with Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)

Depemokimab Delivers Clinically Meaningful and Statisti...

Mar 3, 2025  0